US 12,357,673 B2
Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
T. C. Wu, Stevenson, MD (US); Chien-Fu Hung, Timonium, MD (US); and Brandon Lam, Baltimore, MD (US)
Assigned to The Johns Hopkins University
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Dec. 23, 2021, as Appl. No. 17/561,606.
Application 17/561,606 is a division of application No. 16/244,200, filed on Jan. 10, 2019, granted, now 11,246,908.
Claims priority of provisional application 62/615,579, filed on Jan. 10, 2018.
Prior Publication US 2022/0211811 A1, Jul. 7, 2022
Int. Cl. C07K 14/475 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/19 (2006.01); A61K 38/38 (2006.01); A61N 5/00 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 14/765 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/1793 (2013.01) [A61K 38/18 (2013.01); A61K 38/19 (2013.01); A61K 38/38 (2013.01); A61N 5/00 (2013.01); A61P 35/00 (2018.01); C07K 14/475 (2013.01); C07K 14/52 (2013.01); C07K 14/765 (2013.01); C07K 16/2827 (2013.01); C07K 19/00 (2013.01); C12N 15/62 (2013.01); A61K 45/06 (2013.01); C07K 2319/31 (2013.01)] 20 Claims
 
1. A method of treating cancer in a mammalian subject in need thereof, comprising:
administering to the mammalian subject an effective amount of a composition comprising a polypeptide comprising albumin protein linked to a FMS-like tyrosine kinase 3 ligand (Flt3L) protein comprising a sequence having at least 80% identity to SEQ ID NO: 1, to thereby treat the cancer in the mammalian subject.